🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05977283
Recruiting Observational

HBsAg Declined Patients Follow-up Study

NCT05977283 · tracked via the Priya Life Science China tracker
Sponsor
Nanfang Hospital, Southern Medical University
Phase
Observational
Started
2023-05-11
Last updated
2024-02-20

Condition(s) studied

Hepatitis BHepatitis B, Chronic

Study summary

The goal of this observational study is to prospectively follow chronic hepatitis B patients who had HBsAg decline in the past 12 months prior to screening. The main question it aims to answer are:

\- Describe treatment pattern and its impact on HBsAg loss in hepatitis B patients who had HBsAg decline in past 12 months due to any reason (with or without new molecular entities therapy).

Participants will be followed up for 36 months after enrollment and may be extended upon expiration according to study objectives.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Participants must have HBsAg decline ≥0.5 log10 IU/mL in past 12 months prior to screening due to any reason (with or without new molecular entities therapy). Among the enrolled subjects, 70% must have HBsAg decline ≥1 log10 IU/mL or actual values ≤3 log10 IU/mL. * Able and willing to provide written informed consent and to comply with the study protocol according to International Council for Harmonization (ICH) and local regulations. Exclusion Criteria: * Any condition which, in the opinion of the investigator, contraindicates their participant in this study. * Participants who are currently participating in interventional clinical study exploring HBV treatment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nanfang Hospital, Southern Medical University Guangzhou Guangdong Recruiting

More Nanfang Hospital, Southern Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05977283 on ClinicalTrials.gov ↗ ← All trials in China